Mubadala Invests $36.5 Million in L-Nutra to Advance Longevity Nutrition Technologies
L-Nutra Inc., the world’s first nutri-technology company advancing science-driven nutrition for longevity and nutrition as medicine, announced a $36.5 million strategic investment from Mubadala Investment Company as part of its Series D funding round, bringing the total Series D raise to $83.5 million.
The investment will support L-Nutra’s global expansion and further advance its clinically validated nutrition programs focused on longevity and medical nutrition.
As part of the agreement, Mubadala and L-Nutra will establish a joint venture and manufacturing hub in Abu Dhabi, dedicated to producing best-in-class medical nutrition therapies and longevity nutrition solutions for the Middle East and North Africa (MENA) region. The collaboration has already initiated healthier nutrition and education programs across seven schools in Abu Dhabi.
Commenting on the investment, Ismail Ali Abdulla, Executive Director at Mubadala’s UAE Investment Platform, said:
“This investment reinforces Abu Dhabi’s ambition to expand as a regional hub for longevity science, preventive health, and advanced nutrition technologies, and operates as a natural extension of the sector capabilities we are building across the UAE’s emerging life sciences ecosystem.”
Joseph Antoun, MD, PhD, Chairman and CEO of L-Nutra, added:
“As the world’s first nutri-technology company, we have spent decades advancing nutrition R&D and developing effective interventions that can be integrated within healthcare systems to support healthy longevity.”
Founded in 2009 by researcher Valter Longo, L-Nutra is known for its nutrition programs inspired by fasting research and metabolic health, including its flagship product ProLon, a fasting-mimicking nutrition program supported by extensive clinical research.
